COVID-19

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Two Accomplished Biotechnology Innovators

New appointments bring deep research and development expertise and technology innovation to support continued advancement of ReAlta’s EPICC Technology PlatformNORFOLK,…

11 months ago

Ainos Announces $1.75 Million Follow-On Funding

The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023.Use of…

11 months ago

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine…

11 months ago

IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine

Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and…

11 months ago

STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024

DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it…

11 months ago

Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US MarketToronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn…

11 months ago

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

CHICAGO, IL / ACCESSWIRE / January 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

11 months ago

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient RecoveryLATHAM, N.Y.--(BUSINESS…

11 months ago

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands Erasmus Medical Center Erasmus Medical Center OCALA, Fla., Jan.…

11 months ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine…

11 months ago